Title |
Advances in ovarian cancer therapy
|
---|---|
Published in |
Cancer Chemotherapy and Pharmacology, December 2017
|
DOI | 10.1007/s00280-017-3501-8 |
Pubmed ID | |
Authors |
Alexander J. Cortez, Patrycja Tudrej, Katarzyna A. Kujawa, Katarzyna M. Lisowska |
Abstract |
Epithelial ovarian cancer is typically diagnosed at an advanced stage. Current state-of-the-art surgery and chemotherapy result in the high incidence of complete remissions; however, the recurrence rate is also high. For most patients, the disease eventually becomes a continuum of symptom-free periods and recurrence episodes. Different targeted treatment approaches and biological drugs, currently under development, bring the promise of turning ovarian cancer into a manageable chronic disease. In this review, we discuss the current standard in the therapy for ovarian cancer, major recent studies on the new variants of conventional therapies, and new therapeutic approaches, recently approved and/or in clinical trials. The latter include anti-angiogenic therapies, polyADP-ribose polymerase (PARP) inhibitors, inhibitors of growth factor signaling, or folate receptor inhibitors, as well as several immunotherapeutic approaches. We also discuss cost-effectiveness of some novel therapies and the issue of better selection of patients for personalized treatment. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 1 | 33% |
Unknown | 2 | 67% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 67% |
Practitioners (doctors, other healthcare professionals) | 1 | 33% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 513 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 80 | 16% |
Student > Master | 66 | 13% |
Researcher | 56 | 11% |
Student > Ph. D. Student | 47 | 9% |
Student > Doctoral Student | 18 | 4% |
Other | 52 | 10% |
Unknown | 194 | 38% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 94 | 18% |
Medicine and Dentistry | 74 | 14% |
Pharmacology, Toxicology and Pharmaceutical Science | 39 | 8% |
Agricultural and Biological Sciences | 23 | 4% |
Chemistry | 20 | 4% |
Other | 58 | 11% |
Unknown | 205 | 40% |